At the 2019 congress in Barcelona from 27 September to 1 October, the European Society for Medical Oncology (ESMO) proved once again it is a match for ASCO. Scrip shares the main points of the event including Seattle Genetics victory for mid-caps.
Author: Informa Pharma Intelligence
Published: 02 September 2019
Number of pages:3
Scrip shares insights on the eight key talking points after the European Society for Medical Oncology (ESMO) congress held in Barcelona from 27 September through 1 October. The points include,
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.